Celgene

Celgene Corporation is a global integrated biopharmaceutical company prim arily engaged in the discovery, development and commercialization of innovative therapies desi gned to treat cancer and immune-inflammatory related diseases in patients with limited treatment optio ns. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

 

As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. For more information visit: www.gilead.com

 

GILEAD Sciences GmbH

Fraunhoferstr. 17

82152 Martinsried

Phone: 089 899 890 0

Fax: 089 899 890 90

info@gilead.com

Jazz Pharmaceuticals

Wing B, Building 5700

Spires House

John Smith Drive

Oxford Business Park South

Oxford

OX4 2RW

Website: www.jazzpharmaceuticals.com

 

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com. 

medac Gesellschaft für klinische Spezialpräparate mbH

Theaterstr. 6

22880 Wedel

Germany

Telephone: +49 (0) 4103 8006-0

Fax: +49 (0) 4103 8006-100

Email: info@medac.de

Web: www.medac.de

 

medac is a privately held, global pharmaceutical company with a growingpharmaceutical and diagnostics business.

Established 1970 in Northern Germany, medac is specialised in the development, manufacturing and marketing of highly-effective therapeutic and innovative diagnostic products.

Alongside the extensive standard portfolio in core areas including haemato-oncology, urological and autoimmune diseases, medac provides niche therapeutic products and special delivery systems.

Neovii Biotech GmbH

Email: info.germany@neovii.com

Phone (with country code): +49 89 898888 0

Fax (with country code): +49 89 898888 16

Website: www.neovii.com

 

Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological  and immune disorders.
Neovii was founded in 2013 by the acquisition  of Fresenius Biotech  inheriting more than three decades of experience in speciality pharmaceuticals.
Neovii’s global headquarters are located in Rapperswil, Switzerland, its U.S headquarters are in Waltham, MA, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approx. 150 employees and has presence in nearly 60 countries worldwide.

Pfizer Pharma GmbH

Linkstrasse 10, 10785 Berlin
Tel: +49 (0)30 550055-01
Fax +49 (0)30 550054-9999
Email: info@pfizer.de
Web: www.pfizer.com
 
Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. We make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands. Every day, our colleagues work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

RIEMSER Pharma GmbH

The company RIEMSER Pharma GmbH, founded in 1992, is the expert for specialty therapeutics with high unmet medical need. RIEMSER Pharma offers their own product portfolio which covers different therapeutic areas. RIEMSER Pharma acquirers licenses, markets and distributes pharmaceutical products in the areas of dermatology, cardiovascular diseases, infectious diseases, oncology, rheumatology, obesity and medical devices, e.g.: Akynzeo®, the first product to combine two modern active ingredients and effectively protects patients against nausea and vomiting in chemotherapy, Tepadina®, is indicated in combination with other chemotherapy with or without total body irradiation as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation; Vagantin® RIEMSER, currently, the only systemic, non CNS acute and long-term medication for excessive armpit sweating and bite away© a medical device that offers rapid help with itching and swelling caused by insect bites and stings. Technical know-how and expertise in the strictly regulated health markets were brought to the fore. Worldwide the more than 300 approvals, with 30 alone in the last two years, are proof of the success of this strategy.

​

Headquarter Greifswald - Insel Riems

An der Wiek 7

17493 Greif swald – Insel Riems

Hohenzollerndamm 151

14199 Berlin 

​

telephone: +49 30 338427-100

email: info@ri emser.com

URL: www.riemser.com

Mallinckrodt Pharmaceuticals 

Therakos (UK) Limited, 3 Lotus Park, The Causeway, Staines-upon-Thames, Surrey, TW18 3AG, UK.
Tel: +44 (0) 1784 636 700. 
Email: CritCareTKS-TKSInfo@mallinckrodt.com

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. Mallinckrodt is the only provider of integrated systems for the delivery of Extracorporeal Photopheresis (ECP). To learn more about this product, visit www.therakos.co.uk.

Ontime Onboard Courier

Email: onboard@ontimecourier.com
Phone (with country code): + 49 - 89 35 73 73 - 20  

Fax: +49 - 89 35 73 73 - 83
Website: www.onboard-courier.com
Mailing Address: Ontime Onboard Courier GmbH, Alois-Wolfmueller-Str. 8, 80939 Munich, Germany

Since 2003 we have provided more than 22.000 accompanied HSC transports for many acknowledged Registries, Collection Centers and Transplant Centers worldwide. We offer services from and to every location on the globe, mainly delivering on the day of donation. Our goal is to create the best and fastest connection for each individual transport in order to contribute to the recovery of affected patients around the world.
Our experience on all 6 continents serving more than 400 transplant centers guarantees the quality you are looking for.
24/7/365 – multi lingual staff – online tracking – we cover all your needs. or +49-89-357373-20 – contact us to find out more!

​

​

Novartis Israel Ltd.

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Our products are available in more than 180 countries around the world. 
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
More than a decade ago, Novartis was the first company to form a dedicated global business unit to develop and launch innovative oncology medicines that address the unmet medical needs of people with cancer and related diseases.
Today, Novartis Oncology – with more than 10,000 associates in 85 countries – is inspired by patients to revolutionize the research, development and manufacturing of innovative, high-quality medicines that help people live longer, with a better quality of life, giving more time to do the things that matter to them. To do our best for patients, we do not accept the status quo. We work to reach more patients worldwide so that patients and society can benefit as quickly as possible.
 
Mailing address:
P.O. Box 7759
4951729 Petach Tikva
ISRAEL

 

Phone: +972 3 9201101; +972 54 5211437
Fax: +972 3 9002842
Email: Tal.vardi@novartis.com

​

MolMed S.p.A.

Email: info@molmed.com
Phone (with country code): +39 0221277.1 Fax +39 02 21277.325
Website: www.molmed.com

MolMed is a biotech company focused on innovative cell&gene therapies for unmet medical needs in cancer and rare diseases. Its pipeline includes: Zalmoxis®, a cell therapy enabling bone marrow transplants from partially compatible donors without post-transplant immune-suppression, in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation in the EU; NGR-hTNF, a novel therapeutic agent for solid tumours, investigated in a broad clinical programme involving more than 1000 patients; CAR-CD44v6, an immune-gene therapy project in preclinical development with broad therapeutic potential for blood cancers and epithelial tumours. MolMed also offers to third parties market-grade development and manufacturing services in cell and gene therapy. MolMed is listed on the main market of the Milan stock exchange

Miltenyi Biotec

Phone: +49 2204 8306-0 
Fax: +49 2204 85197 
macs@miltenyibiotec.de
www.miltenyibiotec.com

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 1,800 employees in 25 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.

Sanofi Genzyme

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

​

​

​

Janssen. More to life than living.

As the pharmaceutical division of the Johnson & Johnson group of healthcare companies, we collaborate with local and international partners to develop innovative medicines and holistic treatment concepts – from diagnosis to rehabilitation. Our therapeutic focus areas are oncology, immunology, neuroscience and infectious diseases. Through our work we aim to deliver what patients really want: the ability to experience everyday events and special moments the way they did before their diagnosis. More than 40,000 people work for Janssen worldwide. Janssen-Cilag GmbH in Neuss, Germany, employs about 800 people.

 

More information can be found at www.janssen.com/germany and
www.mehr-leben-im-Leben.de.

​

​

Kiadis Pharma B.V.

Entrada 231-234, 1114 Amsterdam-Duivendrecht, The Netherlands
Tel: +31 (0) 20 314 02 50
Fax: +31 (0) 20 314 02 51
Email: communication@kiadis.com

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective.
Kiadis Pharma is focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company’s product candidates are ATIR101™ for blood cancers and ATIR201™ for inherited blood disorders. Based on the significant and positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, the Company has initiated a Phase III trial with ATIR101™, having received regulatory approval in various countries to start dosing patients. In addition, and based on the positive Phase II results, the Company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ATIR101™ across Europe as an adjunctive treatment in HSCT for malignant disease. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.
The Company’s second product candidate, ATIR201™, addresses inherited blood disorders with an initial focus on thalassemia. ATIR201™ Phase I/II clinical development has been initiated with regulatory approvals having been received in various European countries to start the trial.
Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA. The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels.

​